Piramal Enterprises Limited

Piramal Life Sciences Limited

Maggie Rathos

Kalpana Sanjay Joshi

Veena R Agarwal

Sreesha Srinivasa

Giridharan Periyasamy

Ankita Srivastava

Somesh Sharma

Sanjay Kumar

Asha Adrian Kulkarni-Almeida

Sapna Parikh

Meenakshi Sivakumar

Malcolm Mascarenhas

Vijaykumar Bhagwan Deore

Nilesh Dagia

Ankush Gangaram Sarde

Pramod Kumar Jadhav

Manoj Shukla

Mandar Bhonde

Nilambari Nilkanth Yewalkar

Amol Arun Padgaonkar

Nikhil Krishnamurthy Hebbar

Harshal Khanwalkar

Ankush Sarde

The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in the treatment of melanoma. The present invention also relates to a method for the treatment of melanoma comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor.

Pharmaceutical combination for the treatment of melanoma

The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of formula I or a pharmaceutically acceptable salt or a solvate thereof. The present invention also relates to a method for the treatment of cancer, which method comprises administering to a patient in need of such a treatment, a therapeutically effective amount of the combination. The present invention also relates to the use of a CDK inhibitor selected from the compounds of formula I as a radiosensitizer that enhances the efficacy of radiotherapy for the treatment of cancer, particularly head and neck cancer.

Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer

A novel pharmaceutical combination comprising a cytotoxic antineoplastic agent selected from a the group consisting of paclitaxel, docetaxel, doxorubicin and gemcitabine or a pharmaceutically acceptable salt thereof and at least one cyclin dependent kinase (CDK) inhibitor; wherein the said combination exhibits synergistic effects when used in the treatment of cancer. The invention also relates to a method for the treatment of cancer, using a therapeutically effective amount of the said combination.

Synergistic pharmaceutical combination for the treatment of cancer

The present invention relates to an enantiomerically pure (+)-trans enantiomer of a compound represented by the following formula (I): wherein R, R, R, Rand Rare as defined in the specification; enantiomerically pure intermediates thereof, to processes for the preparation of the enantiomerically pure compound and its intermediates, and to a pharmaceutical composition comprising the enantiomerically pure compound. The compound of formula (I) is useful for the treatment of diseases or disorders mediated by the inhibition of cyclin dependant kinase, such as cancer.

Enantiomerically pure compounds for the treatment of proliferative disorders

The present invention relates to pyridyl derivatives capable of inhibiting phosphatidylinositol-3-kinase (PI3k), mammalian target of rapamycin (mTOR) and/or hypoxia inducible factor 1&#x3b1; (HIF-1&#x3b1;) mediated signaling. Also disclosed are processes for preparation of the pyridyl derivatives, and their use in the manufacture of pharmaceutical compositions for the treatment of clinical conditions caused by deregulation of signaling pathways selected from one or more of PI3K, mTOR and HIF-1&#x3b1; pathways. The pyridyl derivatives are also useful for the treatment of conditions or disorders mediated by TNF-&#x3b1;.

Pyridyl derivatives, their preparation and use

Growing community of inventors

Mumbai, India

Maggie Rathos